September 19, 2018

September 18, 2018

Subscribe to Latest Legal News and Analysis

September 17, 2018

Subscribe to Latest Legal News and Analysis

California Supreme Court Ends Glyphosate Debate, for the Time Being

One week after a San Francisco jury decided against Monsanto and awarded a plaintiff $289 million due to the alleged exposure that caused his cancer, the California Supreme Court refused to hear any further challenges by Monsanto as to whether California’s Office of Environmental Health Hazard Assessment (OEHHA) properly relied upon a 2015 International Agency for Research on Cancer report in determining that glyphosate is a carcinogen and therefore products containing it are subject to Prop 65 warnings.

The decisions are unrelated but as the saying goes: “timing is everything.”

As previously addressed in this space (July 31, 2017 post, here), Monsanto’s quest was initially rejected by a trial court in Fresno, Monsanto Co. v. Office of Envtl. Health Hazard Assessment. The California Court of Appeal, Fifth District, rejected the same argument in April of this year. In May, Monsanto appealed to the California Supreme Court while the Supreme Court refused to stay the requirement for a warning to be placed on the product during the pendency of the appeal. The Court docket reflects that only Justice Ming Chin voting for review.

Monsanto, in an August 15 statement, said it is considering options for further legal action.

“There is no scientific basis to list glyphosate under Prop 65,” the company said. “The listing contradicts 40 years of science and the conclusions of regulatory bodies around the world.”

The fight still rages on the Federal court in Sacramento as described in several prior posts (January 11, 2018 post, here, and March 5, 2018 post, here).

©1994-2018 Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. All Rights Reserved.

TRENDING LEGAL ANALYSIS


About this Author

Daniel Herling, product liability, attorney, Mintz Levin, law firm
Member

Dan’s practice is focused on product liability issues relating to consumer products. 

Specific to consumer class action lawsuits, Dan has successfully defended clients in class actions alleging false or misleading labeling or advertising of foods, cosmetics, over-the-counter drugs, dietary supplements, and homeopathic products. These claims have involved probiotics, “natural” ingredients, “clinically-proven” results, lack of efficacy, lack of substantiation, and failure to disclose. 

415-432-6103